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How might ePharma research 
impact the patient experience? 
•  Data linkage for scaled validation of clinical trial results   
–  Real world intelligence for iterating guidelines & translational R&D 
•  Identifying signals of actual and potential ADEs  
–  Early drug withdrawal or reformulation  
–  Reduced patient discomfort & risk, better QoL  
–  Understanding patient mediators for better stratified prescribing 
•  Demonstrating effects of Polypharmacy in natural experiments 
–  Interactions not yet causing harm 
–  Serendipidous associations 
•  Linking primary care prescribing data with clinical data   
–  Informing personalised & stratified treatments 
•  Cost effective analytics  
–  Cost-effective prescribing 
–  Value proposition for society 
•  ADRs -> 5-30% of hospital admissions in US, Australia, Europe  
•  Tip of the iceberg, many go unreported  
•  RCTs poor detectors. Small samples. Unrealistic controlled 
settings. Few opportunities to examine behavioral and patient 
modifiers. Not powered to detect micro effects. 
•  Scaled clinical data linkage holds great potential, and 
pharmacovigilance is the most advanced application of 
these methods so far 
 
•  But this is only part of the story… 
•  Patient reported ADRs hold promise 
–  What are the best ways to do this? 
     
Detecting Adverse Drug Reactions 
Mobiles & Clinical Trial Coordination 
Pharmaceutical industry investing in 
mobile platforms for trial coordination 
&  data management 
 
Potential to speed translation to 
innovations for patient care 
 
Companies springing up to fill this gap 
 
Mostly data collection platforms, 
mobile form submission, updating 
protocols 
 
Moving towards patient-reported 
outcomes … 
 
 
•  75% of people unaware of clinical studies  
•  Around half of all trials don’t fill their recruitment quotas   
•  Not just scientists ‘pushing’ risky trials to patients 
•  Many patients want and seek engagement 
•  But risks of suggesting that ‘experimental’ is better 
Online awareness raising 
Direct-to-patient trial recruitment 
 “After six hours, we have 7,406 
people enrolled in our Parkinson’s 
study. Largest one ever before was 
1,700 people” (Tweet from 
Parkinsons app developer, May 
2015) 
 
Stanford Uni cardiovascular trial 
attracted 11,000 volunteers in one 
day after releasing their ‘MyHeart 
Counts’ App in the App Store. It 
would normally take a year to enroll 
that many subjects (Bloomberg 
Business, March 2015) 
 
Early days. Sampling challenges 
(noise, representativeness), but 
great potential…. 
Clinical Trials & Data Quality 
Patient Recruitment 
Expense & inconvenience limit numbers & generalizability. 
Recruiting via apps could open up a population of potential 
trial participants. 700 million iPhone users   
 
Data Objectivity 
Trial data can be subjective (e.g. symptom ratings) & 
clinical data can be flawed. ICT can generate quantifiable 
metrics e.g. exercise (actigraphy), biomonitoring 
(embedded sensors & linked peripherals), self-report tools 
etc.  May reduce false reporting by patients 
 
Data Frequency 
80% - 90% of iPhone users keep them within arm’s length 
27/7. “We’re trying to change the scale of the data that we 
can collect, from data collected every three months, to 
every second.”    Apple Executive, quoted in Forbes 
Business, March 9th 
 
Data quality – “Many Carbon 
Monoxide poisonings may have 
been intentional rather than 
accidental, raising questions for 
national reporting (Miller, Pagliari 
et al, IoM, 2011) 
 
“Google X is building a wearable health 
sensor for cardiac and activity tracking, 
but it isn’t a Fitbit or Apple Watch 
competitor: Google’s device is a clinical-
grade sensor designed for investigational 
use” MobiHealthNews, June 23rd 
The new wearables 
Linked to HealthKit, the Apple 
Watch can track blood glucose, 
heart rate, blood pressure, exercise 
and much more. Being portrayed 
as everything from a personal 
lifestyle checker to a cure for 
cancer. 
Coming soon 
Home-based telemonitoring is gaining traction but mHealth is the future 
Google-Novartis Diabetes Monitoring Contact Lens 
Patented Jan 2015.  Others following e.g. Medella Health 
The data captured as we interact with digital technologies and 
services, have potential to provide a phenotypic footprint, useful for 
research, diagnostics, prognostics and personalised medicine 
Multiple channels: 
•  Web searches 
•  Social media 
•  Mobile apps 
•  Wearables 
•  Smart homes  
•  Internet of Things 
•  TV habits, Shopping etc. 
Digital Phenotype 
Jain et al May 2015. Nature Innovation 
Taylor, Pagliari, Osborne (2013). How Gestational 
Diabetes is Discussed on Twitter 
Using Society’s Data Trails 
New Responsibilites for 
Govt & Pharma? 
Looking to communities for 
innovative research 
May 9, 2015 
“The first patient-driven 
campaign to find and fund 
critical research for high-risk 
multiple myeloma patients” 
http://mcri.myelomacrowd.org. 
 
Ethics 
Davison, Pagliari, Cunningham-Burley et al (2012) 
•  Making the most of data from research repositories, clinical 
records and patients requires a new understanding of concepts 
like ‘science’, ‘personalised’, ‘ownership’ & ‘privacy’ 
•  Managing the tense intersection between academic & 
commercial research remains a barrier, and the dividing line is 
often blurred 
•  Our social & policy research is seeking to establish the 
boundaries of the social contract and inform the wider data 
science agenda for the UK and beyond 
Scot Gov Social 
Research, 2012 
 
 
 
 
Patient Record Access & Trust   
Enabling patients to access and question their data may help to 
build trust in research, identify errors, and support trial recruitment 
 
Pharmacists asked us to identify controls, so I put the call out…I have 3000 patients with access 
to their records. When they know what they’re sharing they have more trust. It only took 6 hours 
to find the 80 or so patients that were needed!...“The key was that patients had been carefully 
consented. If people know what they’re signing up for and what the risks are, they won’t be as 
inclined to fear it later” (Amir Hannan) 
Pinciroli & Pagliari (2015) 
Building capacity 
www.eHealth.ed.ac.uk 
•  eHealth is multidisciplinary, multi-platform, cross-sectoral & global 
•  Rounded eHealth professionals are vital for future research, policy & 
practice 
 
claudia.pagliari@ed.ac.uk 
Twitter: @EeHRN 
LinkedIn: https://uk.linkedin.com/pub/claudia-pagliari/6/32/a53 
Researchgate: www.researchgate.net/profile/Claudia_Pagliari 
eHealth@ed.ac.uk 
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